Status:
UNKNOWN
Cardiac Steatosis in Cushing's Syndrome
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Endocrine System Disease
Cardiovascular Imaging
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This study aims at evaluating the myocardial triglyceride content and cardiac structure and function, using 1H magnetic resonance spectroscopy and cardiac magnetic resonance imaging, in patients with ...
Detailed Description
Despite skeletal muscle atrophy, Cushing's syndrome patients have an increased Left Ventricular mass, reversible upon correction of the hypercortisolism. This may be due to cardiac steatosis, previous...
Eligibility Criteria
Inclusion
- group 1 and 2: patients with overt Cushing's syndrome, with 24-hour urinary free cortisol excretion over the two fold of the upper limit of the normal, with (group 1) or without (group 2) diabetes mellitus or glucose intolerance
- group 3: healthy volunteers matched for age, sex and BMI with the patients of the group 2
Exclusion
- contraindication of MRI
- hypersensitivity to gadolinium
- acute myocardial ischemia
- renal insufficiency (creatinin clearance 30 mL/min/l,73m2)
- pregnancy
Key Trial Info
Start Date :
June 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT02202902
Start Date
June 1 2014
End Date
December 1 2017
Last Update
September 29 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AP-HP, Bicêtre Hospital
Le Kremlin-Bicêtre, France, 94275